US.EW · Edwards Lifesciences

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.1019359464627145,
        "turnoverUsdM": 365.81791472000003,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.EW",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 78.4886,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 1,
        "rsi_score": 2.5,
        "macd_score": 1,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.2,
      "take_profit_price": 87.864,
      "target_multiplier": 1.6,
      "technical_strength": 1.5,
      "take_profit_percent": 5
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.203871892925429,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 51,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 48,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 88.6905,
    "ma50": 87.3342,
    "close": 83.68,
    "prevClose": 83.04,
    "avgVolume20": 5116651,
    "volumeRatio": 0.85,
    "changePercent": 0.77
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.010289769367238244,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.860831406865969,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.008080250524241,
      "volat_points": 0,
      "day_range_pct": 0.02688814531548757,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 51,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 54,
        "contribution": 2.7
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 5.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 36,
        "contribution": 5.4
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.5,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 65,
        "contribution": 6.5
      },
      {
        "raw": 13,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 43.33,
        "contribution": 13
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 48,
    "details": [
      "基本面分析總分: 2.7/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 5.4/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.5/10分",
      "技術信號分析總分: 13/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 2.7,
      "資金流": 8.4,
      "市場環境": 5.4,
      "情緒分析": 6,
      "技術信號": 13,
      "風險管理": 6.5
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 365.81791472000003,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.EW",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.67
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 708.0634979000001,
                "ma50": 716.7494019999999,
                "name": "QQQ",
                "close": 675.48999,
                "points": 0.4
              },
              "spy": {
                "ma20": 746.6510067000002,
                "ma50": 744.8574021799999,
                "name": "SPY",
                "close": 740.85999,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.1019359464627145,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141037316,
                "url": "https://finnhub.io/api/news?id=20190819d5293f8bb8dc1b1f77910f7a4721d08607b709d03904590042fdd75f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "On July 23, Edwards Lifesciences Corporation (NYSE:EW) delivered second-quarter 2026 net sales of $1.74 billion, up 13.6% year over year (12.5% on a constant currency basis), surpassing Wall Street expectations of $1.70 billion. Adjusted diluted earnings per share came in at $0.78, ahead of the consensus estimate of $0.74 and up 16.4% from $0.67 a […]",
                "category": "company",
                "datetime": 1785183627,
                "headline": "Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion?"
              },
              {
                "id": 141016117,
                "url": "https://finnhub.io/api/news?id=c3025646096062355f708ef9b445ef39446ddbc9439e0796a71dc0983a28989f",
                "image": "",
                "source": "Fintel",
                "related": "EW",
                "summary": "",
                "category": "company",
                "datetime": 1784984157,
                "headline": "Leerink Partners Upgrades Edwards Lifesciences (EW)"
              },
              {
                "id": 141014148,
                "url": "https://finnhub.io/api/news?id=c78de666c8ec263549d7c2acf32328d18d87b576b14ef340657b7e52347ddff6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences stock sits at an interesting spot for valuation focused investors, with the Discounted Cash Flow (DCF) based intrinsic value estimate suggesting the shares are roughly in line with underlying cash flow assumptions, while the broader checks still point to a stock that does not screen as cheap and has delivered a decline over five years. Over the past 5 years, Edwards Lifesciences has delivered a total return that is down 26.4%, which raises the question of whether the...",
                "category": "company",
                "datetime": 1784956267,
                "headline": "Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium"
              },
              {
                "id": 141002771,
                "url": "https://finnhub.io/api/news?id=5e742edd1cfd6865d6cf619e68b6ba9dde8febc21f2134a81974aa461f25fde4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences Corp (EW) reports a robust 12.5% sales increase, driven by innovation and strategic growth across key segments.",
                "category": "company",
                "datetime": 1784869255,
                "headline": "Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ..."
              },
              {
                "id": 141000935,
                "url": "https://finnhub.io/api/news?id=b99123e1d67cf454598568b8bca7d8c1f4f88c3eea773da97cb08a71f3c9251a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
                "category": "company",
                "datetime": 1784844003,
                "headline": "Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates"
              },
              {
                "id": 140998825,
                "url": "https://finnhub.io/api/news?id=7beb6bec9acf77d6f736316b476aa5087289cc1e2a06e562a78ba100f0bb3f45",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Edwards Lifesciences reported Q2 2026 earnings in line with estimates, posted $0.78 EPS, and raised full-year sales guidance, driving a 6.2% after-hours stock surge.",
                "category": "company",
                "datetime": 1784839844,
                "headline": "Edwards Lifesciences (NYSE:EW) Raises Guidance After Solid Q2 Earnings, Stock Surges 6%"
              },
              {
                "id": 141001227,
                "url": "https://finnhub.io/api/news?id=f4a67de60aa7747ebbf060fe66009e855382029447385d79005f0b76cfa8bf03",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call July 23, 2026 5:00 PM EDTCompany ParticipantsGerianne Sarte - Investor Relations OfficerBernard...",
                "category": "company",
                "datetime": 1784838632,
                "headline": "Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 140768835,
                "url": "https://finnhub.io/api/news?id=36383ca999e0e2d8c2c95f816b33e0074c375d4162675966285778927441e0f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing evidence across its aortic, mitral and tricuspid transcatheter valve therapies, including PROGRESS, PARTNER 3, EARLY TAVR, PASCAL and SAPIEN M3 programs. An important takeaway is how the PROGRESS trial’s baseline data on moderate aortic stenosis and long-term durability findings for SAPIEN 3 deepen understanding of earlier, less invasive treatment options for complex...",
                "category": "company",
                "datetime": 1782778531,
                "headline": "Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference"
              }
            ],
            "raw_source": [
              {
                "id": 141042644,
                "url": "https://finnhub.io/api/news?id=7507ca35b1cbe8e76ab6c5b9c089fdd29418dcb58a04e57f6822f7749625c588",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1785245664,
                "headline": "Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls"
              },
              {
                "id": 141040714,
                "url": "https://finnhub.io/api/news?id=c0dcf572278a87fdc5bdf02ed6d81b218534ccffed862d9b68a0f1bba5309517",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "DUBLIN, July 28, 2026--CroíValve, a clinical-stage medical device company developing the DUO™ transcatheter tricuspid coaptation valve system, today announced the appointment of Jaime Wheeler, MBA, CPhT, as Chief Executive Officer. In conjunction with this, Lucy O’Keeffe will transition into the role of Chief Operating Officer where she will support Jaime in delivering CroíValve’s mission of innovating a better way to treat tricuspid regurgitation (TR). Jaime is a transformational healthcare exe",
                "category": "company",
                "datetime": 1785223800,
                "headline": "CroíValve Announces the Appointment of Jaime Wheeler as Chief Executive Officer"
              },
              {
                "id": 141037316,
                "url": "https://finnhub.io/api/news?id=20190819d5293f8bb8dc1b1f77910f7a4721d08607b709d03904590042fdd75f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "On July 23, Edwards Lifesciences Corporation (NYSE:EW) delivered second-quarter 2026 net sales of $1.74 billion, up 13.6% year over year (12.5% on a constant currency basis), surpassing Wall Street expectations of $1.70 billion. Adjusted diluted earnings per share came in at $0.78, ahead of the consensus estimate of $0.74 and up 16.4% from $0.67 a […]",
                "category": "company",
                "datetime": 1785183627,
                "headline": "Edwards Lifesciences (EW)’s TMTT Revenue Surges 47%: Can Rapid Growth Drive the Next Leg of Earnings Expansion?"
              },
              {
                "id": 141016117,
                "url": "https://finnhub.io/api/news?id=c3025646096062355f708ef9b445ef39446ddbc9439e0796a71dc0983a28989f",
                "image": "",
                "source": "Fintel",
                "related": "EW",
                "summary": "",
                "category": "company",
                "datetime": 1784984157,
                "headline": "Leerink Partners Upgrades Edwards Lifesciences (EW)"
              },
              {
                "id": 141014148,
                "url": "https://finnhub.io/api/news?id=c78de666c8ec263549d7c2acf32328d18d87b576b14ef340657b7e52347ddff6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences stock sits at an interesting spot for valuation focused investors, with the Discounted Cash Flow (DCF) based intrinsic value estimate suggesting the shares are roughly in line with underlying cash flow assumptions, while the broader checks still point to a stock that does not screen as cheap and has delivered a decline over five years. Over the past 5 years, Edwards Lifesciences has delivered a total return that is down 26.4%, which raises the question of whether the...",
                "category": "company",
                "datetime": 1784956267,
                "headline": "Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium"
              },
              {
                "id": 141005872,
                "url": "https://finnhub.io/api/news?id=74fe11d832993c0a9ab47eef2a14c7c38da71f7011ef32455844d38d129c56ab",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Friday. Discover the gap up and gap down stocks in the S&P500 index.",
                "category": "company",
                "datetime": 1784903701,
                "headline": "Friday's session: gap up and gap down stock in the S&P500 index"
              },
              {
                "id": 141006595,
                "url": "https://finnhub.io/api/news?id=37c5f3d4f6cf608cf606099c2250e66aa4c45e9928fe2dfee311c50b74f9ce74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences stock launched higher Friday after the medtech company beat Wall Street's top- and bottom-line expectations.",
                "category": "company",
                "datetime": 1784903038,
                "headline": "Edwards, The 'Cleanest Large-Cap Medtech Story,' Launches On Second-Quarter Beat"
              },
              {
                "id": 141008589,
                "url": "https://finnhub.io/api/news?id=90adc2bfc27e86084efb037010c27e173264ef197937243fdcee8ddb947bc636",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "JP Morgan  analyst Robbie Marcus   maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.",
                "category": "company",
                "datetime": 1784900766,
                "headline": "JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105"
              },
              {
                "id": 141005405,
                "url": "https://finnhub.io/api/news?id=70bfa83ccbba1d01ee7ccb7f4e996315592255d14809a1f1e015ac69caced29b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1784899968,
                "headline": "SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls"
              },
              {
                "id": 141005473,
                "url": "https://finnhub.io/api/news?id=7e5c1ee50c7bd031d2b9de1613cc78cef1c03319d1995635d0efc1439e84fa19",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.",
                "category": "company",
                "datetime": 1784899135,
                "headline": "Edwards lifts FY26 growth outlook following steady Q2 performance"
              },
              {
                "id": 141006524,
                "url": "https://finnhub.io/api/news?id=32051c07b4e7a4e0c1418e8e01970f2ac0db8656ab65fcebe5b9d5274caa4129",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.",
                "category": "company",
                "datetime": 1784897640,
                "headline": "Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises"
              },
              {
                "id": 141008590,
                "url": "https://finnhub.io/api/news?id=423ca23e4ad3509ce029759ad75854628ba77b80c037b50fb1f815ead64a96e2",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Piper Sandler  analyst Adam Maeder   reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.",
                "category": "company",
                "datetime": 1784896678,
                "headline": "Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101"
              },
              {
                "id": 141004719,
                "url": "https://finnhub.io/api/news?id=ab72008a4b23c5002a67cdd879c5165c836f6ad4e946cb7eaf13fce827bc33f2",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
                "category": "company",
                "datetime": 1784896500,
                "headline": "These S&P500 stocks are moving in today's pre-market session"
              },
              {
                "id": 141016332,
                "url": "https://finnhub.io/api/news?id=25f374e33cec0eb53c275bea4d9bd66481a25b48a7153304586f183620521c1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Moby summary of Edwards Lifesciences Corporation's Q2 2026 earnings call",
                "category": "company",
                "datetime": 1784896200,
                "headline": "Edwards Lifesciences Corporation Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141008591,
                "url": "https://finnhub.io/api/news?id=7a82389b504b8ccc03147bb02d1992bb5df2759106591c3310e2847917101868",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/Irvine--California---7-May-2023-Edwards-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.",
                "category": "company",
                "datetime": 1784893695,
                "headline": "Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says"
              },
              {
                "id": 141008029,
                "url": "https://finnhub.io/api/news?id=b2424bef56873a8554028ac6ef1baac437d1a795399281013938d4c76246c938",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "An upcoming Medicare coverage decision for transcatheter aortic valve replacement devices and study readout for patients with moderate disease are expected to help the company maintain its momentum.",
                "category": "company",
                "datetime": 1784892392,
                "headline": "Edwards posts strong TAVR sales ahead of potential Medicare coverage expansion"
              },
              {
                "id": 141005802,
                "url": "https://finnhub.io/api/news?id=a70b07018e3a368ce5ffe7fc9eba41d0c1a04a50606c7c0079ca0c378506ec56",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/Wall-Street.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "U.S. stock futures were higher on Friday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Thursday's lower close.",
                "category": "company",
                "datetime": 1784883752,
                "headline": "Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Oil Prices Decline—Intel, Edwards Lifesciences, SAP in Focus (UPDATED)"
              },
              {
                "id": 141002771,
                "url": "https://finnhub.io/api/news?id=5e742edd1cfd6865d6cf619e68b6ba9dde8febc21f2134a81974aa461f25fde4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences Corp (EW) reports a robust 12.5% sales increase, driven by innovation and strategic growth across key segments.",
                "category": "company",
                "datetime": 1784869255,
                "headline": "Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ..."
              },
              {
                "id": 141008337,
                "url": "https://finnhub.io/api/news?id=9dd6072c4dff5a6fc4f9f7ef11ba6af85796b34185b3d5d9fb06ba505bccf295",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/American-Express-Platinum-amex-Platinum-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "US stock futures mixed, focus on companies like American Express, Deckers, Verizon, Edwards Lifesciences, and HCA Healthcare for today's trading.",
                "category": "company",
                "datetime": 1784859381,
                "headline": "American Express, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday"
              },
              {
                "id": 141000934,
                "url": "https://finnhub.io/api/news?id=d69a1c01d1e43d2c894bb1de45fcca0057d7171a005b6b78db88582e348149f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products. Chief Executive Officer Bernard Zovighian said the",
                "category": "company",
                "datetime": 1784847981,
                "headline": "Edwards Lifesciences Q2 Earnings Call Highlights"
              },
              {
                "id": 141000935,
                "url": "https://finnhub.io/api/news?id=b99123e1d67cf454598568b8bca7d8c1f4f88c3eea773da97cb08a71f3c9251a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
                "category": "company",
                "datetime": 1784844003,
                "headline": "Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates"
              },
              {
                "id": 140999713,
                "url": "https://finnhub.io/api/news?id=3dd0b827f131d78c22045ed45fe4009f4d0efca7d573b08b6179be9aac9bef3f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences stock launched higher Thursday after the medtech company beat Wall Street's top- and bottom-line expectations.",
                "category": "company",
                "datetime": 1784841288,
                "headline": "Edwards Stock Launches As Heart-Valve Replacements Beat On"
              },
              {
                "id": 140999050,
                "url": "https://finnhub.io/api/news?id=d32847d0307152ac4528851d0189d27c3f79291e50e1560ca3d49c3033173e86",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top S&P500 gainers and losers driving the post-market movements.",
                "category": "company",
                "datetime": 1784840701,
                "headline": "Which S&P500 stocks are moving after the closing bell on Thursday?"
              },
              {
                "id": 140998825,
                "url": "https://finnhub.io/api/news?id=7beb6bec9acf77d6f736316b476aa5087289cc1e2a06e562a78ba100f0bb3f45",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Edwards Lifesciences reported Q2 2026 earnings in line with estimates, posted $0.78 EPS, and raised full-year sales guidance, driving a 6.2% after-hours stock surge.",
                "category": "company",
                "datetime": 1784839844,
                "headline": "Edwards Lifesciences (NYSE:EW) Raises Guidance After Solid Q2 Earnings, Stock Surges 6%"
              },
              {
                "id": 141001227,
                "url": "https://finnhub.io/api/news?id=f4a67de60aa7747ebbf060fe66009e855382029447385d79005f0b76cfa8bf03",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call July 23, 2026 5:00 PM EDTCompany ParticipantsGerianne Sarte - Investor Relations OfficerBernard...",
                "category": "company",
                "datetime": 1784838632,
                "headline": "Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 140999714,
                "url": "https://finnhub.io/api/news?id=50971ac8fc6d458186caa23186c6cbb56df2590de183c7a1adbee31c4d5dcc3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IRVINE, Calif., July 23, 2026--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026.",
                "category": "company",
                "datetime": 1784837700,
                "headline": "Edwards Lifesciences Reports Second Quarter Results"
              },
              {
                "id": 140998874,
                "url": "https://finnhub.io/api/news?id=e5ba571ed4be393c5c05c23003ab3cbe4fbd4d46a5ba91afa3e959186b2a9c40",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) is looking for Q3 Adj EPS of $0.71-$0.77 vs $0.74 analyst estimate. sees sales of $1.630 billion-$1.710 billion vs $1.689 billion analyst estimate.",
                "category": "company",
                "datetime": 1784823417,
                "headline": "Edwards Lifesciences Sees Q3 Adj EPS $0.71-$0.77 vs $0.74 Est; Sees Sales $1.630B-$1.710B vs $1.689B Est"
              },
              {
                "id": 140998875,
                "url": "https://finnhub.io/api/news?id=6ba372496fc63fec1418eb67db9aad66621b71f18f3d37b860fc78d8e6066c85",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) affirms FY2026 Adj EPS guidance from $2.95-$3.05 to $2.95-$3.05 vs $3.01 analyst estimate. Raises FY2026 sales outlook from $6.500 billion-$6.900 billion to $6.600 billion-$6.900 billion",
                "category": "company",
                "datetime": 1784823370,
                "headline": "Edwards Lifesciences Affirms FY2026 Adj EPS Guidance of $2.95-$3.05 vs $3.01 Est; Raises FY2026 Sales Guidance from $6.500B-$6.900B to $6.600B-$6.900B vs $6.745B Est"
              },
              {
                "id": 140998876,
                "url": "https://finnhub.io/api/news?id=84dc80c0a89fee1667f417cd038d00e39479d38e89180a3f811b4886f393cc67",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.74 by 5.41 percent. This is a 16.42 percent increase over earnings of $0.67 per share from",
                "category": "company",
                "datetime": 1784823335,
                "headline": "Edwards Lifesciences Q2 Adj. EPS $0.78 Beats $0.74 Estimate, Sales $1.741B Beat $1.700B Estimate"
              },
              {
                "id": 140996690,
                "url": "https://finnhub.io/api/news?id=85af9e8893acc6773c696c8ffbce2fa38f27f38ee6fd643adf77b9f3130959f1",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1784813736,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140993809,
                "url": "https://finnhub.io/api/news?id=a47ad7f0bc8a271af3493561d9e532c43ff1705e233807236e6b2cf91a6dc883",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Companies Reporting Before The Bell\n• Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. \n• Dime Commercial (NYSE:DCOM) is expected to report",
                "category": "company",
                "datetime": 1784790711,
                "headline": "Earnings Scheduled For July 23, 2026"
              },
              {
                "id": 140960859,
                "url": "https://finnhub.io/api/news?id=97af80ad8ab4420f78a1207f54a4d08df4680ba053061f1404d83440a6f0dda2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "EW heads into Q2 earnings results with estimates calling for double-digit revenue growth as TAVR, TMTT and Surgical heart businesses remain in focus.",
                "category": "company",
                "datetime": 1784553780,
                "headline": "Edwards' Q2 Earnings on the Horizon: What's in the Cards?"
              },
              {
                "id": 140923844,
                "url": "https://finnhub.io/api/news?id=32da7eb77d4992ff3dda71d86dac896e66f7a630f14de4145a045b2bb87a9692",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Truist Securities  analyst Richard Newitter   maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $90 to $95.",
                "category": "company",
                "datetime": 1784203176,
                "headline": "Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95"
              },
              {
                "id": 140918806,
                "url": "https://finnhub.io/api/news?id=9ce29e8a103f05ede7f01b3cc8dc6fdfea85964c53b145569e6e0d2ce4bf97e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IRVINE, Calif., July 16, 2026--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.",
                "category": "company",
                "datetime": 1784199900,
                "headline": "Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026"
              },
              {
                "id": 140923845,
                "url": "https://finnhub.io/api/news?id=c1bc6bd2c0bc50ee5f997e20172409d41e1d2a6a2254bcba8ee487a35ae39698",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Mizuho  analyst Anthony Petrone   maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $105.",
                "category": "company",
                "datetime": 1784125451,
                "headline": "Mizuho Maintains Outperform on Edwards Lifesciences, Raises Price Target to $105"
              },
              {
                "id": 140900008,
                "url": "https://finnhub.io/api/news?id=046fa9e725fbd21c8d4cd5bb04dc474ca78380f1c2a35257e14f172cdc026a53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The FTC secured the penalty after a court ruled that Edwards failed to comply with antitrust law requirements when it acquired JC Medical in 2024.",
                "category": "company",
                "datetime": 1784046736,
                "headline": "Edwards Lifesciences served $10m penalty over JC Medical acquisition violations"
              },
              {
                "id": 140891355,
                "url": "https://finnhub.io/api/news?id=7a86d3baa26466a4ba265293463d7e0d19d79051b37231f79e80188e97b14440",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "(Bloomberg) -- The Federal Trade Commission urged a judge to block Henkel AG’s $725 million purchase of part of Pittsburgh Paint Co., saying the deal would harm competition in the liquid-adhesive market by combining two of its biggest players.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Restarts Iran Blockade as US Plans 20% Hormuz ChargeTrump Embraces Australian Retirement System Backed by Larry FinkOpenAI Engineer’s ‘LOL’ Moment Set Stage for Legal Fig",
                "category": "company",
                "datetime": 1783969528,
                "headline": "FTC Says Henkel Deal Would Merge ‘Coke and Pepsi’ of Adhesives"
              },
              {
                "id": 140891424,
                "url": "https://finnhub.io/api/news?id=2583080fb9cb1dc1a1aa6630bcae89cf976a37974a965d1b7dcfe37c7df91053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The artificial heart valve maker will settle allegations it deliberately structured its deal to acquire JC Medical to sidestep a Hart-Scott-Rodino review.",
                "category": "company",
                "datetime": 1783962134,
                "headline": "Edwards will pay $10M to settle FTC charges of skirting antitrust review"
              },
              {
                "id": 140887430,
                "url": "https://finnhub.io/api/news?id=50fe240da8205292fac353b41a2e4a121dd417b1cab90129dc3c7f2770e48eb0",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "RBC Capital  analyst Shagun Singh   maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $110.",
                "category": "company",
                "datetime": 1783937734,
                "headline": "RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $110"
              },
              {
                "id": 140841554,
                "url": "https://finnhub.io/api/news?id=f808f463d5f0bb22dc96f28672fbc2e037f5d169cc4a1ef4e380aa09c200209e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The market is focused on today's costs, but the company has already sold a future that looks entirely different.",
                "category": "company",
                "datetime": 1783523487,
                "headline": "The One Number That Could Rewrite the Story for CoreWeave Stock"
              },
              {
                "id": 140840980,
                "url": "https://finnhub.io/api/news?id=f6b89872007a09af68ad6c31154624cb9a96d205fade79b74bd2350ac6679dce",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/08/Merck-Logo--Sign-At-Merck-Research-Labor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Wall St analysts changed outlook on top names. KBW cut AON PT to $400, Barclay's cut T PT to $24, MS cut ROL PT to $65, GS cut SAM PT to $169, BofA raised ALLY PT to $53, Citi raised EW PT to $110, Wells Fargo raised MRK PT to $150, Jefferies raised ENVA PT.",
                "category": "company",
                "datetime": 1783500020,
                "headline": "Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday"
              },
              {
                "id": 140844806,
                "url": "https://finnhub.io/api/news?id=e38a7c2046c3ef3ec12c87a213c329f67f1639c81b63531e57a13e266418537b",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Citigroup  analyst Joanne Wuensch   maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $101 to $110.",
                "category": "company",
                "datetime": 1783493221,
                "headline": "Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $110"
              },
              {
                "id": 140825083,
                "url": "https://finnhub.io/api/news?id=d4831a06a8b6f7f3feb8ad73f380bfa82b004b8eec49a45e787a5b8408bd3d1d",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Evercore ISI Group  analyst Vijay Kumar   maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $93 to $100.",
                "category": "company",
                "datetime": 1783339812,
                "headline": "Evercore ISI Group Maintains Outperform on Edwards Lifesciences, Raises Price Target to $100"
              },
              {
                "id": 140785971,
                "url": "https://finnhub.io/api/news?id=9417d92376a940320b0658b48d238996e548963863d2897c4d2a6cdaa04c2ccb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences is scheduled to report its second-quarter results soon, and analysts expect a single-digit earnings rise.",
                "category": "company",
                "datetime": 1782923534,
                "headline": "What You Need To Know Ahead of Edwards Lifesciences' Earnings Release"
              },
              {
                "id": 140772402,
                "url": "https://finnhub.io/api/news?id=29928c6dad2caaf8f5b48d7ed19e8c0bf20103ebebf8dcb587da59e9c1cee1d6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Orlando--Fl--Usa---January-20--2022-Dard.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Canaccord cut Strategy's target, Barclays upgraded Watts Water, Rosenblatt boosted Comcast, Goldman increased State Street, Evercore raised Owens Corning, Cantor Fitzgerald boosted BioCryst Pharma, BTIG raised Edwards Lifesciences.",
                "category": "company",
                "datetime": 1782810296,
                "headline": "Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday"
              },
              {
                "id": 140774055,
                "url": "https://finnhub.io/api/news?id=67d042810efc8c2c01c9cd0720b35451092be688f1c6d77f410c83941db8fe06",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "BTIG  analyst Marie Thibault   maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $100 to $110.",
                "category": "company",
                "datetime": 1782806186,
                "headline": "BTIG Maintains Buy on Edwards Lifesciences, Raises Price Target to $110"
              },
              {
                "id": 140768835,
                "url": "https://finnhub.io/api/news?id=36383ca999e0e2d8c2c95f816b33e0074c375d4162675966285778927441e0f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing evidence across its aortic, mitral and tricuspid transcatheter valve therapies, including PROGRESS, PARTNER 3, EARLY TAVR, PASCAL and SAPIEN M3 programs. An important takeaway is how the PROGRESS trial’s baseline data on moderate aortic stenosis and long-term durability findings for SAPIEN 3 deepen understanding of earlier, less invasive treatment options for complex...",
                "category": "company",
                "datetime": 1782778531,
                "headline": "Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference"
              },
              {
                "id": 140765508,
                "url": "https://finnhub.io/api/news?id=114499e6dd4eaa6ca7fb68293857493880ef5d632bdbecc410078617b2bb4682",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Intuitive Surgical's Quintuple Aim strategy is driving premium pricing as da Vinci 5 adoption grows, with innovation-led revenue growth outpacing procedure growth.",
                "category": "company",
                "datetime": 1782754560,
                "headline": "Can ISRG's 'Quintuple Aim' Strategy Continue to Justify Premium Pricing?"
              },
              {
                "id": 140764119,
                "url": "https://finnhub.io/api/news?id=2558ab0870b5c4bd52b22a6d7cbb6ec5c9eb3d3645adb5a45d03774f7d39dc10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences (EW) can sustain a high revenue growth rate given its technological leadership",
                "category": "company",
                "datetime": 1782750579,
                "headline": "Edwards Lifesciences Can Sustain Strong Revenue Growth on Technological Leadership, RBC Says"
              },
              {
                "id": 140764120,
                "url": "https://finnhub.io/api/news?id=15115c8ddf386bc50ddc3fb9d01795b6c1cbd80a889b327a585df6d4ea69da48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.",
                "category": "company",
                "datetime": 1782731798,
                "headline": "Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 50,
            "discarded_article_count": 42
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 13,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.5,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.5,
            "vcp_reason": "升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 2,
              "vol_ref": 5209106.666666667,
              "down_days": 7,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 6255700,
              "avg_vol_20": 5078380,
              "avg_vol_30": 5209106.666666667,
              "range_pct_10": 0.11316921606118545,
              "range_pct_20": 0.1808078393881454,
              "range_pct_30": 0.1808078393881454,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.2009160879792569,
              "dist_to_20d_high": 0.13095856267525183,
              "down_shrink_days": 2,
              "breakout_level_20d": 96.29,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.6259087904824847
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.1019359464627145,
              "turnoverUsdM": 365.81791472000003,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.EW",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 78.4886,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 1,
              "rsi_score": 2.5,
              "macd_score": 1,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.2,
            "take_profit_price": 87.864,
            "target_multiplier": 1.6,
            "technical_strength": 1.5,
            "take_profit_percent": 5
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.203871892925429,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 2.5957,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.1
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -85.13
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1659
    },
    "kdj": {
      "d": 14.54,
      "j": 25.95,
      "k": 18.35,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 28.29
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -12779371,
      "recentSlope": -1942437.1,
      "previousSlope": -1556300
    },
    "rsi": 16.71,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 87.4239,
      "position": "SAR喺價上",
      "distancePct": 4.47,
      "previousTrend": "下降"
    },
    "ma50": 87.3342,
    "macd": {
      "macd": -1.4636660893227997,
      "trend": "看跌",
      "signal": -0.5773514455176461,
      "histogram": -0.8863146438051537
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 88.0522,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.85,
      "score": 4,
      "avgVolume": 5116651,
      "currentVolume": 4371629
    },
    "derived": {
      "ma20": 88.6905,
      "ma50": 87.3342,
      "prevClose": 83.04,
      "avgVolume10": 6167943,
      "avgVolume20": 5116651,
      "changePercent": 0.77,
      "avgVolumeForScore": 5116651
    },
    "ma_cross": {
      "ma20": 88.6905,
      "ma50": 87.3342,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 89.0655,
      "prevMa50": 87.2874,
      "spreadPct": 1.55,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 80.2076,
      "upper": 97.1734,
      "position": "中間"
    },
    "rsi_short": 30.7,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.85
    }
  }
}

{
  "close": 83.68,
  "volume": 4371629,
  "changePercent": 0.77
}